RU2016144187A - Твердые формы фармацевтически активного соединения - Google Patents
Твердые формы фармацевтически активного соединения Download PDFInfo
- Publication number
- RU2016144187A RU2016144187A RU2016144187A RU2016144187A RU2016144187A RU 2016144187 A RU2016144187 A RU 2016144187A RU 2016144187 A RU2016144187 A RU 2016144187A RU 2016144187 A RU2016144187 A RU 2016144187A RU 2016144187 A RU2016144187 A RU 2016144187A
- Authority
- RU
- Russia
- Prior art keywords
- solid form
- form according
- theta
- values
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (18)
1. Твердая форма соединения (1)
выбранная из:
a) по существу аморфной формы соединения (1);
b) полугидрата, гидрата, полусольвата или сольвата соединения (1); или
c) полиморфа соединения (1); или
d) фармацевтически приемлемой соли соединения (1).
2. Твердая форма по п. 1, отличающаяся тем, что она представляет собой полиморф, гидрат, полугидрат, сольват, полусольват или фармацевтически приемлемую соль.
3. Твердая форма по п. 1, отличающаяся тем, что она представляет собой аморфную форму.
4. Твердая форма по п. 1 или 2, характеризуемая дифрактограммой РПД (рентгеновская порошковая дифракция) со значениями 2 тета 4,9, 6,9, 7,7, 9,1, 10,9, 13,5, 14,5, 17,2, 20,4, 22,3 и 25,5.
5. Твердая форма по п. 1 или 2, характеризуемая дифрактограммой РПД со значениями 2 тета 4,1, 5,0, 5,7, 6,3, 6,9, 7,9, 8,1, 9,0, 10,0, 14,3 и 19,5.
6. Твердая форма по п. 1 или 2, характеризуемая дифрактограммой РПД со значениями 2 тета 5,9, 8,3, 9,5, 10,1, 11,3, 14,2, 15,8, 17,6, 19,0, 19,4, 19,8, 20,3 и 25,5.
7. Твердая форма по п. 1 или 2, характеризуемая дифрактограммой РПД со значениями 2 тета 5,1, 8,0, 8,3, 8,8, 9,3, 10,0, 10,3, 13,7, 14,3, 18,7, 20,2, 20,8 и 27,6.
8. Твердая форма по п. 1 или 2, характеризуемая дифрактограммой РПД со значениями 2 тета 3,9, 7,8, 8,7, 9,1, 13,7, 14,5, 18,2 и 20,3.
9. Твердая форма по п. 1 или 2, характеризуемая дифрактограммой РПД со значениями 2 тета 5,5, 7,4, 14,5, 14,8, 15,6, 16,9, 17,8, 18,6, 19,9, 20,5, 24,8 и 26,7.
10. Твердая форма по п. 1 или 2, характеризуемая дифрактограммой РПД со значениями 2 тета 6,6, 10,7, 14,6, 15,7, 16,0, 16,4, 18,9, 19,8, 21,4, 22,0, 25,3 и 26,1.
11. Твердая форма по п. 3, характеризуемая волновыми числами в спектре ИК-Фурье (инфракрасная спектроскопия на основе преобразования Фурье), см-1: 1705, 1687, 1600, 1587, 1525, 1483, 1409, 1367, 1343, 1299, 1276, 1250, 1230, 1221, 1178, 1128, 1086, 1034, 902, 885, 817, 778, 765 и 729.
12. Фармацевтическая композиция, содержащая одну или несколько твердых форм, охарактеризованных в любом из пп. 1-11, вместе с фармацевтически приемлемыми адъювантами или эксципиентами.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461979649P | 2014-04-15 | 2014-04-15 | |
| US61/979,649 | 2014-04-15 | ||
| PCT/EP2015/057937 WO2015158648A1 (en) | 2014-04-15 | 2015-04-13 | Solid forms of a pharmaceutically active compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016144187A true RU2016144187A (ru) | 2018-05-16 |
| RU2016144187A3 RU2016144187A3 (ru) | 2018-11-13 |
Family
ID=52815005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016144187A RU2016144187A (ru) | 2014-04-15 | 2015-04-13 | Твердые формы фармацевтически активного соединения |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10227298B2 (ru) |
| EP (2) | EP3131878A1 (ru) |
| JP (2) | JP6621761B2 (ru) |
| KR (1) | KR20160138307A (ru) |
| CN (1) | CN106458886A (ru) |
| AR (1) | AR100095A1 (ru) |
| AU (1) | AU2015249018A1 (ru) |
| BR (1) | BR112016023767A2 (ru) |
| CA (1) | CA2943571A1 (ru) |
| ES (1) | ES2928706T3 (ru) |
| IL (1) | IL247974A0 (ru) |
| MA (1) | MA39877A (ru) |
| MX (1) | MX2016013439A (ru) |
| PL (1) | PL3459933T3 (ru) |
| RU (1) | RU2016144187A (ru) |
| SG (1) | SG11201608559QA (ru) |
| WO (1) | WO2015158648A1 (ru) |
| ZA (1) | ZA201606653B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
| WO2019213106A1 (en) | 2018-04-30 | 2019-11-07 | Teva Pharmaceuticals International Gmbh | Solid state forms of idasanutlin |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| US8993614B2 (en) * | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| US20130245089A1 (en) * | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
| US9216170B2 (en) * | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| CN107540594A (zh) * | 2012-05-30 | 2018-01-05 | 霍夫曼-拉罗奇有限公司 | 取代的吡咯烷‑2‑甲酰胺 |
| WO2014114575A1 (en) * | 2013-01-22 | 2014-07-31 | F. Hoffmann-La Roche Ag | Pharmaceutical composition with improved bioavailability |
| PL2958893T3 (pl) | 2013-02-21 | 2017-09-29 | F.Hoffmann-La Roche Ag | Asymetryczna synteza podstawionego pirolidyno-2-karboksyamidu |
-
2015
- 2015-04-13 MA MA039877A patent/MA39877A/fr unknown
- 2015-04-13 MX MX2016013439A patent/MX2016013439A/es unknown
- 2015-04-13 US US15/303,792 patent/US10227298B2/en not_active Expired - Fee Related
- 2015-04-13 AU AU2015249018A patent/AU2015249018A1/en not_active Abandoned
- 2015-04-13 RU RU2016144187A patent/RU2016144187A/ru not_active Application Discontinuation
- 2015-04-13 ES ES18200578T patent/ES2928706T3/es active Active
- 2015-04-13 WO PCT/EP2015/057937 patent/WO2015158648A1/en active Application Filing
- 2015-04-13 CA CA2943571A patent/CA2943571A1/en not_active Abandoned
- 2015-04-13 CN CN201580019543.0A patent/CN106458886A/zh active Pending
- 2015-04-13 EP EP15714843.8A patent/EP3131878A1/en not_active Withdrawn
- 2015-04-13 JP JP2016562779A patent/JP6621761B2/ja active Active
- 2015-04-13 PL PL18200578.5T patent/PL3459933T3/pl unknown
- 2015-04-13 BR BR112016023767A patent/BR112016023767A2/pt active Search and Examination
- 2015-04-13 SG SG11201608559QA patent/SG11201608559QA/en unknown
- 2015-04-13 EP EP18200578.5A patent/EP3459933B1/en active Active
- 2015-04-13 KR KR1020167031690A patent/KR20160138307A/ko not_active Application Discontinuation
- 2015-04-15 AR ARP150101148A patent/AR100095A1/es unknown
-
2016
- 2016-09-22 IL IL247974A patent/IL247974A0/en unknown
- 2016-09-26 ZA ZA2016/06653A patent/ZA201606653B/en unknown
-
2018
- 2018-11-05 JP JP2018207854A patent/JP6887980B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6621761B2 (ja) | 2019-12-18 |
| ES2928706T3 (es) | 2022-11-22 |
| CN106458886A (zh) | 2017-02-22 |
| SG11201608559QA (en) | 2016-11-29 |
| JP6887980B2 (ja) | 2021-06-16 |
| RU2016144187A3 (ru) | 2018-11-13 |
| MA39877A (fr) | 2017-02-22 |
| AU2015249018A1 (en) | 2016-10-06 |
| JP2019055960A (ja) | 2019-04-11 |
| CA2943571A1 (en) | 2015-10-22 |
| EP3131878A1 (en) | 2017-02-22 |
| US20170037005A1 (en) | 2017-02-09 |
| EP3459933B1 (en) | 2022-08-24 |
| AR100095A1 (es) | 2016-09-07 |
| WO2015158648A1 (en) | 2015-10-22 |
| EP3459933A2 (en) | 2019-03-27 |
| EP3459933A3 (en) | 2019-05-29 |
| MX2016013439A (es) | 2016-11-17 |
| KR20160138307A (ko) | 2016-12-02 |
| JP2017511362A (ja) | 2017-04-20 |
| PL3459933T3 (pl) | 2023-01-23 |
| ZA201606653B (en) | 2018-05-30 |
| IL247974A0 (en) | 2016-11-30 |
| BR112016023767A2 (pt) | 2017-08-15 |
| US10227298B2 (en) | 2019-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016146119A (ru) | Новый кристалл тетрациклического соединения | |
| WO2017100726A8 (en) | Methods for treating huntington's disease | |
| HRP20190842T1 (hr) | Kristalni oblici 2-((4s)-6-(4-hlorofenil)-1-metil-4h-benzo[c]izoksazolo[4,5-e]azepin-4-il)acetamida | |
| WO2017075629A3 (en) | Wee 1 kinase inhibitors and methods of making and using the same | |
| CN106536480A8 (zh) | 吡咯烷‑2,5‑二酮衍生物、药物组合物及用作ido1抑制剂的方法 | |
| RU2020110358A (ru) | Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор- пиридин-3-ил]-пиразоло[1,5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы | |
| WO2015195656A3 (en) | Synthesis of polycyclic-carbamoylpyridone compounds | |
| WO2015000431A9 (zh) | 替唑尼特氨基甲酸酯及其在药学中的应用 | |
| GB2562556B (en) | Thumbnail Generation from Panoramic Images | |
| WO2016100732A3 (en) | Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives | |
| RU2016144187A (ru) | Твердые формы фармацевтически активного соединения | |
| TN2018000188A1 (en) | Isoindole compounds | |
| EA201591530A1 (ru) | Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции | |
| JP2015173751A5 (ru) | ||
| EP3523984A4 (en) | SUPERPOSITION BASED WAVE SYNTHESIS APPARATUS AND METHODS | |
| WO2016024286A3 (en) | An improved process for synthesis of lenalidomide | |
| WO2017053555A8 (en) | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs | |
| EA201690735A1 (ru) | Кристаллические формы s-ацетилглутатиона, их получение и применения в фармацевтических и нутрицевтических композициях | |
| BR112017003715A2 (pt) | método para sintetizar peneiras moleculares de silicoaluminofosfato-34 usando monoisopropanol amina | |
| JP2019518052A5 (ru) | ||
| IL247567B (en) | Process for liquid phase synthesis of h-inp-(d)bal-(d)trp-phe-apc-nh2 and its salts suitable for pharmaceutical use | |
| RU2017108908A (ru) | Замещенное в положении c-4" макролидное производное | |
| WO2014155371A3 (en) | Crystalline lenalidomide process | |
| GB2587853B (en) | High density brine internal phase | |
| JP2015063566A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190304 |